SCA
ONC icon

Stuart Chaussee & Associates’s BeOne Medicines Ltd ONC Stock Holding History

Stuart Chaussee & Associates’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3
Closed -$1K – 243
2021
Q1 		$1K Buy
+3
New +$993 ﹤0.01% 244

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Stuart Chaussee & Associates's ONC Position: Q2 2021 in Review

Stuart Chaussee & Associates sold out of BeOne Medicines Ltd (ONC) in Q2 2021, closing a stake of 3 shares — an estimated $1K sold.

Stuart Chaussee & Associates first reported a position in ONC in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 268 funds tracked by Wall St. Rank hold ONC as of Q2 2021.

  • Stuart Chaussee & Associates reported no remaining BeOne Medicines Ltd position as of Q2 2021 after selling out during the quarter.
  • Stuart Chaussee & Associates sold 3 BeOne Medicines Ltd shares in Q2 2021, an estimated $1K.
  • Stuart Chaussee & Associates first reported a position in BeOne Medicines Ltd in Q1 2021 and held it in 1 quarter.
  • Stuart Chaussee & Associates's BeOne Medicines Ltd position peaked at $1K in Q1 2021.
  • 268 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2021.

Based on Stuart Chaussee & Associates's 13F filing for Q2 2021, filed 6 Aug 2021.